CVS Pharmacy has agreed to pay $315 million to settle US government allegations that it unlawfully dispensed thousands of opioid and other controlled-substance prescriptions before seeking reimbursement from Medicare and other federal healthcare programmes.
The settlement, announced by the US Department of Justice on Tuesday, resolves claims relating to conduct alleged to have taken place between 17 October 2013 and 2 December 2025. Prosecutors said CVS breached the Controlled Substances Act and the False Claims Act.
The government alleged that pharmacists filled prescriptions for excessive quantities of opioids, supplied medicines earlier than permitted and dispensed so-called “trinity” combinations involving an opioid, a benzodiazepine and a muscle relaxant.
CVS was also accused of accepting prescriptions from suspected “pill mill” providers who issued large volumes of controlled-substance orders without a legitimate medical purpose. Prosecutors said pharmacists proceeded despite warning signs that prescriptions might be invalid or medically unnecessary.
The complaint further alleged that corporate performance targets, incentive payments and staffing policies placed pressure on pharmacists to prioritise speed and commercial results over patient safety. The government said some pharmacies did not have enough staff to meet both customer demand and legal obligations, while pharmacists were allegedly prevented from sharing warnings about problematic prescribers.
Alongside the financial settlement, CVS has entered into a memorandum of agreement with the US Drug Enforcement Administration. The company will be required to operate a hotline for employees and members of the public to report suspected illegal dispensing, monitor dispensing patterns across its pharmacies and review prescribers flagged for questionable activity.
Assistant Attorney General Brett Shumate said the additional safeguards would help ensure opioids and other controlled substances were dispensed only when medically appropriate.
Associate Attorney General Stanley E Woodward Jr described the agreement as a significant step in the Justice Department’s efforts to combat the opioid epidemic. DEA assistant administrator Cheri Oz said the agency remained committed to holding pharmacies accountable for unsafe dispensing practices.
CVS said it strongly disagreed with the allegations and that the settlement did not amount to an admission of wrongdoing. The company has previously argued that its pharmacists were being judged against unclear and changing standards when deciding whether opioid prescriptions should be filled.
The case began with a whistleblower action brought by Hillary Estright, a former CVS employee, under the False Claims Act. The Justice Department intervened in 2024, and Estright’s share of any recovery has yet to be determined.
The claims resolved by the agreement remain allegations. No finding of liability has been made against CVS.
